Adult Burkitt LymphomaBL-TOXNCT07895927
Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational Study
An observational study of Adult Burkitt Lymphoma and Chemotherapy-Related Toxicity, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Burkitt lymphoma is a rare, highly aggressive B-cell non-Hodgkin lymphoma in adults. Although intensive multi-agent chemotherapy can achieve high complete remission rates, it is associated with substantial toxicity, morbidity, and sometimes treatment-related mortality. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adult Burkitt Lymphoma, Chemotherapy-Related Toxicity, Overall and Progression-Free Survival
- How many people
- 25 participants
- Where
- 1 siteFrance
- Study dates
- 11 Feb 2026to 11 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with Burkitt lymphoma managed at Strasbourg University Hospitals and/or ICANS between January 1, 2009, and December 31, 2025, whose medical records are available and who meet the eligibility criteria
Who may be able to join
- Adults aged 18 years or older.
- Patients diagnosed with Burkitt lymphoma at Strasbourg University Hospitals between January 1, 2009, and December 31, 2025, and/or managed by the Hematology Department of Strasbourg University Hospitals or ICANS for Burkitt lymphoma during this period.
- No written objection documented in the medical record to the reuse of personal data for scientific research.
Who cannot join
- Patients who have objected to the reuse of their personal data for scientific research.
- Patients diagnosed with another B-cell non-Hodgkin lymphoma other than Burkitt lymphoma.
- Patients for whom accessible data are unavailable.
- Individuals under legal protection (sauvegarde de justice).
- Individuals under guardianship or curatorship (tutelle or curatelle).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service d'Hématologie et d'Oncologie - CHU de Strasbourg, France
Strasbourg, 67091
Marie-Pierre Ledoux, MD, 33 3 68 76 74 07, mariepierre.ledoux@chru-strasbourg.fr
Marie-Pierre Ledoux, MD
About this study
Official title: Retrospective Observational Study of Intensive First-Line Treatments for Adult Burkitt Lymphoma at Strasbourg University Hospitals
Burkitt lymphoma is a rare, highly aggressive B-cell non-Hodgkin lymphoma in adults. Although intensive multi-agent chemotherapy can achieve high complete remission rates, it is associated with substantial toxicity, morbidity, and sometimes treatment-related mortality. This retrospective, single-center observational study aims to characterize the short- and long-term complications of intensive first-line treatment in adults with Burkitt lymphoma managed at Strasbourg University Hospitals.
The study will evaluate treatment-related toxicities, overall survival at five years, and progression-free survival at 24 months. Secondary objectives include assessing treatment delays, chemotherapy dose reductions, and their associations with toxicity, disease location at diagnosis, and survival.
All eligible adult patients diagnosed with Burkitt lymphoma or managed for this condition at Strasbourg University Hospitals and the ICANS between January 1, 2009, and December 31, 2025, will be considered. The study will use retrospective medical record data, with no a priori sample size calculation because of the rarity of the disease and the single-center design.
- Conditions
- Adult Burkitt Lymphoma, Chemotherapy-Related Toxicity, Overall and Progression-Free Survival
- Keywords
- Burkitt Lymphoma, Intensive First-Line Treatment, Treatment-Related Toxicity
- Medical subject headings
- Burkitt Lymphoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment-Related Toxicity
Incidence of different toxicities during intensive first-line treatment for adult Burkitt lymphoma
Measured: Retrospective assessment of patients treated between January 1, 2009, and December 31, 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2026
- Study start11 Feb 2026
- Primary completion11 Feb 2027 (estimated)
- Study completion11 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adult Burkitt LymphomaStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07895927
- Sponsor's protocol ID
- RC25_0127
- Acronym
- BL-TOX
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective Observational Study of Intensive First-Line Treatments for Adult Burkitt Lymphoma at Strasbourg University Hospitals
- ClinicalTrials.gov ID
- NCT07895927
- Acronym / sponsor ID
- BL-TOX / RC25_0127
- Conditions
- Adult Burkitt Lymphoma, Chemotherapy-Related Toxicity, Overall and Progression-Free Survival
- Keywords
- Burkitt Lymphoma, Intensive First-Line Treatment, Treatment-Related Toxicity
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 11 Feb 2026 (actual)
- Primary completion
- 11 Feb 2027 (estimated)
- Study completion
- 11 Apr 2027 (estimated)
- First posted
- 26 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Burkitt lymphoma is a rare, highly aggressive B-cell non-Hodgkin lymphoma in adults. Although intensive multi-agent chemotherapy can achieve high complete remission rates, it is associated with substantial toxicity, morbidity, and sometimes treatment-related mortality. This retrospective, single-center observational study aims to characterize the short- and long-term complications of intensive first-line treatment in adults with Burkitt lymphoma managed at Strasbourg University Hospitals.
The study will evaluate treatment-related toxicities, overall survival at five years, and progression-free survival at 24 months. Secondary objectives include assessing treatment delays, chemotherapy dose reductions, and their associations with toxicity, disease location at diagnosis, and survival.
All eligible adult patients diagnosed with Burkitt lymphoma or managed for this condition at Strasbourg University Hospitals and the ICANS between January 1, 2009, and December 31, 2025, will be considered. The study will use retrospective medical record data, with no a priori sample size calculation because of the rarity of the disease and the single-center design.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with Burkitt lymphoma managed at Strasbourg University Hospitals and/or ICANS between January 1, 2009, and December 31, 2025, whose medical records are available and who meet the eligibility criteria
Key inclusion criteria (3 listed)
- Adults aged 18 years or older.
- Patients diagnosed with Burkitt lymphoma at Strasbourg University Hospitals between January 1, 2009, and December 31, 2025, and/or managed by the Hematology Department of Strasbourg University Hospitals or ICANS for Burkitt lymphoma during this period.
- No written objection documented in the medical record to the reuse of personal data for scientific research.
Key exclusion criteria (5 listed)
- Patients who have objected to the reuse of their personal data for scientific research.
- Patients diagnosed with another B-cell non-Hodgkin lymphoma other than Burkitt lymphoma.
- Patients for whom accessible data are unavailable.
- Individuals under legal protection (sauvegarde de justice).
- Individuals under guardianship or curatorship (tutelle or curatelle).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Treatment-Related Toxicity
Time frame: Retrospective assessment of patients treated between January 1, 2009, and December 31, 2025
Incidence of different toxicities during intensive first-line treatment for adult Burkitt lymphoma
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
Related trials for Adult Burkitt Lymphoma
RecruitingPhase 3
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia
RecruitingPhase 3
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
RecruitingPhase 1/2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
RecruitingObservational study
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Hematologic Malignancy, Leukemia
RecruitingPhase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adult Burkitt Lymphoma and Chemotherapy-Related Toxicity, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marie-Pierre LEDOUX, MD (33 3 68 76 74 07, mariepierre.ledoux@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment-Related Toxicity (time frame: Retrospective assessment of patients treated between January 1, 2009, and December 31, 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.